Latest for Mucopolysaccharidosis Type IVA
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNo longer enrolling. Early Check: Expanded Screening in Newborns (RTI International)ClinicalTrials.gov
More about Mucopolysaccharidosis Type IVA
The skeletal features of Morquio A are distinctive: short trunk with a barrel-shaped chest, knock knees, spinal curvature, and joint laxity that together cause significant mobility challenges. Cervical spine instability from odontoid hypoplasia is a serious complication that can lead to spinal cord compression and paralysis. Respiratory function declines as the ribcage deformity restricts lung expansion.
Keep reading about Mucopolysaccharidosis Type IVA
Heart valve disease, corneal clouding, and hearing loss add to the disease burden. The FDA approved Vimizim (elosulfase alfa), an enzyme replacement therapy by BioMarin, on February 14, 2014 as the first treatment for MPS IVA. It is given into a vein once a week at 2mg per kg of body weight, over at least 3.5 to 4.5 hours.
In its main trial, people on Vimizim walked 22.5 meters farther in 6 minutes than people on placebo after 24 weeks, and it lowered keratan sulfate in urine. The label has a boxed warning for severe allergic reactions, including anaphylaxis, and says people with a breathing illness at the time of infusion may have serious breathing problems and need extra monitoring.
What are the symptoms of Mucopolysaccharidosis Type IVA?
These are common symptoms of Mucopolysaccharidosis Type IVA, and how strong they are varies from person to person.
- Short stature and growth restriction beginning in early childhood
- Kyphoscoliosis and progressive spinal curvature
- Knock-knee deformity (genu valgum) causing difficulty walking
- Barrel chest (pectus carinatum) and rib flaring
- Progressive joint pain, stiffness, and laxity
- Corneal clouding and progressive vision impairment
- Hearing loss that worsens over time
- Heart valve thickening and regurgitation
- Obstructive sleep apnea and respiratory compromise
- Dental abnormalities including thin enamel and widely spaced teeth
Who gets Mucopolysaccharidosis Type IVA?
The severe form typically appears between ages 1 and 3 with skeletal abnormalities becoming obvious as the child grows. A milder, slowly progressive form can appear in late childhood or adolescence. Affects males and females equally.
Autosomal recessive inheritance requiring mutations in both copies of the GALNS gene on chromosome 16. Intelligence is normal, though spinal cord compression from skeletal changes can cause neurological complications.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Mucopolysaccharidosis Type IVA?
There is currently 1 FDA-approved medication for Mucopolysaccharidosis Type IVA.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for Mucopolysaccharidosis Type IVA treatment
Charity funds and drugmaker programs for Mucopolysaccharidosis Type IVA, checked at the source.
- From a charity · National MPS SocietyFamily Assistance Program fundApply directly
Pays for: Specialized equipment and medical aids not covered by insurance (requires insurance denial and 10% family copay), up to $3,000 per year.
The foundation says: “Status not shown on page” - From a charity · National MPS SocietyMedical Travel Assistance Program fundApply directly
Pays for: Travel to out-of-town medical appointments more than 125 miles away (per year), up to $550 per year.
The foundation says: “Status not shown on page” - From a charity · National MPS SocietyJourney Assistance Program fundApply directly
Pays for: Items that ease daily life (40% of purchase price), up to $500 per year.
The foundation says: “Status not shown on page” - From a charity · NORD RareCareMorquio A Syndrome Medical Assistance fundWaitlist
Pays for: Medical and medication costs.
The foundation says: “Temporarily Waitlisting” - From a charity · NORD RareCareMorquio A Syndrome Premium Copay Assistance fundWaitlist
Pays for: Insurance premiums and copays.
The foundation says: “Temporarily Waitlisting”
Every program and fund for Mucopolysaccharidosis Type IVA, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Mucopolysaccharidosis Type IVA
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Mucopolysaccharidosis Type IVA resources
Reputable organizations and medical references for learning more about Mucopolysaccharidosis Type IVA, including disease registries, foundation resources, and clinical guidelines.